← Back
Data updated: Mar 10, 2026
RIDGEBACK BIOTHERAPEUTICS
Infectious DiseaseImmunologyOncology
RIDGEBACK BIOTHERAPEUTICS is a biotechnology company focused on Infectious Disease, Immunology, Oncology.
2020
Since
1
Drugs
-
Trials
2
Approved (2yr)
Key Drugs
No active drugs
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 73%
1 drugs Phase 2: 1
Immunology 18%
0 drugs Phase 2: 1
Oncology 9%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Merck big-pharma
Oncology, Infectious Disease, Immunology
AbbVie big-pharma
Immunology, Oncology, Infectious Disease
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Immunology
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-12-21
- Latest
- 2026-02-18
- Applications
- 1